header logo ru2

 

10 facts web



CHECKMATE 920

 
A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
 
 Phase 4, 200 patients
 Last updated: April 09, 2018
 STATUS: Ongoing not recruiting (per ClinicalTrials.gov/NCT02982954)

WHO

is the trial for?

Patients with kidney cancer (Renal Cell Carcinoma, RCC) who currently meet the following criteria:
  • histologically confirmed advanced or metastatic Renal Cell Carcinoma
  • previously untreated (treatment-naive) disease
  • no prior systemic therapy for kidney cancer except for one prior adjuvant or neoadjuvant therapy
  • overall health status has to be good (Karnofsky Performance Status (KPS) of at least 70% for cohort 1, 2, and 3; KPS of 50-60% for cohort 4)

WHAT

is the key question that this trial is attempting to answer?

The purpose of this phase 4 study is to investigate the safety of the combination of the immune-checkpoint inhibitors nivolumab and ipilimumab in patients with previously untreated advanced or metastatic Renal Cell Carcinoma.

WHY

patients might want to participate?

This clinical trial offers patients an opportunity to access a new therapy that may be effective for kidney cancer. This trial will support further research in kidney cancer and potentially help other patients with kidney cancer. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.

WHEN

will the trial be open?

This study is ongoing and not recruiting – 200 patients currently participate.

WHERE

is the trial available?

The trial will be available in various cancer centres in the USA. For a complete list of trial locations, please click here: Trial locations Checkmate 920

STUDY

DESIGN

What does the study look like?

There will be 4 cohorts (groups): all participating patients will be divided into four groups according their kidney cancer diagnosis:

  • Group 1: Clear-Cell Renal Cell Carcinoma with Karnofsky Performance Status (KPS) ≥ 70%
  • Group 2: Non Clear-Cell Renal Cell Carcinoma (nccRCC) with KPS ≥ 70%
  • Group 3: Renal Cell Carcinoma (RCC) with non-active Brain Metastases, with KPS ≥70%
  • Group 4: Renal Cell Carcinoma (RCC), regardless of any histology or existing non-active brain metastasis, with KPS 50%-60%
All patients will receive a combination of nivolumab + ipilimumab. 
  • nivolumab (Opdivo™) is a fully human monoclonal antibody targeting PD-1 that is already approved for renal cell carcinoma
  • ipilimumab (Yervoy™) is a fully human monoclonal antibody targeting CTLA-4 that is not yet approved for renal cell carcinoma

HOW

do I get more information?

Patient organisations supporting kidney cancer patients in your country may offer additional information about this trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving kidney cancer patients. If there are no such organisations in your country, please email us for more information: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра.

CONNECT

with other patients on this trial

If you want to connect with other patients considering or participating in this trial, you can find them here: List of organisations worldwide.

SHARE

your experience 

If you would like to share your experience on this trial, send us an e-mail to: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра.
Note that your experience would be helpful for other patients and patient organisations.

RESULTS

of the study

No results are available at this time. Future results will be linked here.
Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.
 
Back to clinical trials overview: How can I find a clinical trial for kidney cancer?